MedTrace Logo

A Study of BGM0504 Tablets in Healthy Chinese Subjects

NCT07566572 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-05-05

No results posted yet for this study

Summary

A randomized, open-label, multiple-dose study to evaluate the effects of high-fat meals and different administration conditions (including water intake and fasting time) on the pharmacokinetics of BGM0504 tablets at a dose of 20mg in healthy Chinese participants and to assess its safety and tolerability.

Conditions

  • Chinese Healthy Volunteers

Interventions

DRUG

BGM0504 tablets

Administered p.o.

Sponsors & Collaborators

  • BrightGene Pharmaceutical (Suzhou) Co., LTD

    collaborator UNKNOWN

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-26
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07566572 on ClinicalTrials.gov